TY - JOUR
T1 - Improved patency of transjugular intrahepatic portosystemic shunt
T2 - The efficacy of cilostazol for the prevention of pseudointimal hyperplasia in swine TIPS models
AU - Park, Sang Woo
AU - Cha, In Ho
AU - Kim, Chul Hwan
AU - Jeon, Hae Jeong
AU - Park, Jeong Hee
AU - Hong, Suk-Joo
AU - Lee, In Sik
PY - 2007/7/1
Y1 - 2007/7/1
N2 - Purpose: To investigate the efficacy of oral administration of cilostazol to inhibit pseudointimal/intimal hyperplasia in swine TIPS models. Methods: Successful TIPS creation was carried out in 11 of 12 healthy young pigs (20-25 kg). In the treatment group (n = 6), both cilostazol and aspirin were administered daily, from the first day of TIPS creation. The control group (n = 5) was administered only aspirin. The animals were followed-up for 2 weeks and then killed. The specimen (including portal vein, hepatic parenchymal tract, hepatic vein, and inferior vena cava) and stents were carefully bisected in a longitudinal fashion. The control group was compared with the treatment group by means of a gross and histologic evaluation of the degree of pseudointimal/intimal hyperplasia in the shunt. Results: At the gross evaluation, the control group showed considerably more pseudointimal/intimal hyperplasia than the treatment group. Using microscopic evaluation, there was a statistically significant difference (p < 0.05) in the mean maximum pseudointimal/intimal hyperplasia thickness between the control group (2.97 ± 0.33 mm) and treatment group (0.73 ± 0.27 mm). Conclusion: Oral administration of cilostazol may have been effective in reducing pseudointimal/intimal hyperplasia in swine TIPS models.
AB - Purpose: To investigate the efficacy of oral administration of cilostazol to inhibit pseudointimal/intimal hyperplasia in swine TIPS models. Methods: Successful TIPS creation was carried out in 11 of 12 healthy young pigs (20-25 kg). In the treatment group (n = 6), both cilostazol and aspirin were administered daily, from the first day of TIPS creation. The control group (n = 5) was administered only aspirin. The animals were followed-up for 2 weeks and then killed. The specimen (including portal vein, hepatic parenchymal tract, hepatic vein, and inferior vena cava) and stents were carefully bisected in a longitudinal fashion. The control group was compared with the treatment group by means of a gross and histologic evaluation of the degree of pseudointimal/intimal hyperplasia in the shunt. Results: At the gross evaluation, the control group showed considerably more pseudointimal/intimal hyperplasia than the treatment group. Using microscopic evaluation, there was a statistically significant difference (p < 0.05) in the mean maximum pseudointimal/intimal hyperplasia thickness between the control group (2.97 ± 0.33 mm) and treatment group (0.73 ± 0.27 mm). Conclusion: Oral administration of cilostazol may have been effective in reducing pseudointimal/intimal hyperplasia in swine TIPS models.
KW - Experimental studies
KW - Interventional procedures
KW - Liver
UR - http://www.scopus.com/inward/record.url?scp=36049001493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36049001493&partnerID=8YFLogxK
U2 - 10.1007/s00270-007-9001-1
DO - 10.1007/s00270-007-9001-1
M3 - Article
C2 - 17450400
AN - SCOPUS:36049001493
VL - 30
SP - 719
EP - 724
JO - Cardiovascular Radiology
JF - Cardiovascular Radiology
SN - 7415-5101
IS - 4
ER -